Sajad Hamal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sajad Hamal has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Jay Budoff
Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA
4 shared publications - Divya Birudaraju
Division Of Cardiology, Lundquist Institute For Biomedical Innovation At Harbor-UCLA, Torrance, California, USA
3 shared publications - Lavanya Cherukuri
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, CA, USA
3 shared publications - Ahmed Ghanem
Cardiology Department, The Lundquist Institute, Torrance, USA
2 shared publications - April Kinninger
The Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
2 shared publications - Ferdinand Flores
Lundquist Institute, Harbor-UCLA Medical Center, 1124W Carson Street, Torrance, CA 90502, United States
2 shared publications
Latest Publications
- Open Access
- 12 May 2022
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 12 (3) , 106-116
Serum Thyrotropin Elevation and Coronary Artery Calcification in Hemodialysis Patients
Introduction: Hypothyroidism is highly prevalent in end-stage kidney disease patients, and emerging data show that lower circulating thyroid hormone levels lead to downregulation of vascular calcification inhibitors and coronary artery calcification (CAC) in this population. To date, no studies have examined the association of serum thyrotropin (TSH), the most sensitive and specific single biochemical metric of thyroid function, with CAC risk in hemodialysis patients. Methods: In secondary analyses of patients from the Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients trial, we examined serum TSH levels and CAC risk assessed by cardiac computed tomography scans collected within a 90-day period. We evaluated the relationship between serum TSH with CAC Volume (VS) and Agatston score (AS) (defined as >100 mm3 and >100 Houndsfield Units, respectively) using multivariable logistic regression. Results: Among 104 patients who met eligibility criteria, higher TSH levels in the highest tertile were associated with moderately elevated CAC VS and AS in case-mix-adjusted analyses (ref: lowest tertile): adjusted ORs (95% CIs) 4.26 (1.18, 15.40) and 5.53 (1.44, 21.30), respectively. TSH levels >3.0 mIU/L (ref: ≤3.0 mIU/L) were also associated with moderately elevated CAC VS and AS. In secondary analyses, point estimates of incrementally lower direct free thyroxine levels trended toward elevated CAC VS and AS, although associations did not achieve statistical significance. Conclusions: In hemodialysis patients, higher serum TSH was associated with elevated CAC VS and AS. Further studies are needed to determine if thyroid hormone supplementation can attenuate CAC burden in this population.
- 12 May 2022
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 12 (3) , 106-116
Open AccessSerum Thyrotropin Elevation and Coronary Artery Calcification in Hemodialysis Patients
Introduction: Hypothyroidism is highly prevalent in end-stage kidney disease patients, and emerging data show that lower circulating thyroid hormone levels lead to downregulation of vascular calcification inhibitors and coronary artery calcification (CAC) in this population. To date, no studies have examined the association of serum thyrotropin (TSH), the most sensitive and specific single biochemical metric of thyroid function, with CAC risk in hemodialysis patients. Methods: In secondary analyses of patients from the Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients trial, we examined serum TSH levels and CAC risk assessed by cardiac computed tomography scans collected within a 90-day period. We evaluated the relationship between serum TSH with CAC Volume (VS) and Agatston score (AS) (defined as >100 mm3 and >100 Houndsfield Units, respectively) using multivariable logistic regression. Results: Among 104 patients who met eligibility criteria, higher TSH levels in the highest tertile were associated with moderately elevated CAC VS and AS in case-mix-adjusted analyses (ref: lowest tertile): adjusted ORs (95% CIs) 4.26 (1.18, 15.40) and 5.53 (1.44, 21.30), respectively. TSH levels >3.0 mIU/L (ref: ≤3.0 mIU/L) were also associated with moderately elevated CAC VS and AS. In secondary analyses, point estimates of incrementally lower direct free thyroxine levels trended toward elevated CAC VS and AS, although associations did not achieve statistical significance. Conclusions: In hemodialysis patients, higher serum TSH was associated with elevated CAC VS and AS. Further studies are needed to determine if thyroid hormone supplementation can attenuate CAC burden in this population.
- 1 March 2021
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 35 (3) , 107840
Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial
- 1 March 2021
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 35 (3) , 107840
Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S40
Association Of Serum Fibrinogen Levels With Thoracic Fat Volumes By Cardiac CT: EVAPORATE (Effect Of Vascepa On Improving Coronary Atherosclerosis In People With High Triglycerides (TGL) Taking Statin Therapy) Trial
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S40
Association Of Serum Fibrinogen Levels With Thoracic Fat Volumes By Cardiac CT: EVAPORATE (Effect Of Vascepa On Improving Coronary Atherosclerosis In People With High Triglycerides (TGL) Taking Statin Therapy) Trial
- Open Access
- 30 November 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , 2142-2149
Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone
Objective Recent results from the Cardiovascular (CV) Trial of the Testosterone(T) Trials showed that T treatment of older men with low T was associated with greater progression of non-calcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the T Trial. Methods The CV part of the trial included 170 men aged 65 years or older with low T. Participants received T gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of CV risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. RESULTS Of 170 enrollees, 138 (73 T, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio p-0.0014) indicated that this variable impacted the testosterone effect on non-calcified plaque volume. The statistical model indicated that for every 0.1 change in the waist-hip ratio, the T-induced 12-month change in non-calcified plaque volume increased by 26.96 mm3 (95% confidence interval 7.72, 46.20). Conclusion Among older men with low T treated for one year, greater waist-hip ratio was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.
- 30 November 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , 2142-2149
Open AccessBiomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone
Objective Recent results from the Cardiovascular (CV) Trial of the Testosterone(T) Trials showed that T treatment of older men with low T was associated with greater progression of non-calcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the T Trial. Methods The CV part of the trial included 170 men aged 65 years or older with low T. Participants received T gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of CV risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. RESULTS Of 170 enrollees, 138 (73 T, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio p-0.0014) indicated that this variable impacted the testosterone effect on non-calcified plaque volume. The statistical model indicated that for every 0.1 change in the waist-hip ratio, the T-induced 12-month change in non-calcified plaque volume increased by 26.96 mm3 (95% confidence interval 7.72, 46.20). Conclusion Among older men with low T treated for one year, greater waist-hip ratio was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.